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Hyperhomocysteinemia in Liver Cirrhosis
Mechanisms and Role in Vascular and Hepatic Fibrosis
Elena Ruiz García-Tevijano, Carmen Berasain, José Antonio Rodríguez, Fernando José Corrales,
Roberto Arias, Antonio Martín-Duce, Juan Caballería, José María Mato, Matías Antonio Avila
Abstract—Numerous clinical and epidemiological studies have identified elevated homocysteine levels in plasma as a risk
factor for atherosclerotic vascular disease and thromboembolism. Hyperhomocysteinemia may develop as a conse-
quence of defects in homocysteine-metabolizing genes; nutritional conditions leading to vitamin B6, B12, or folate
deficiencies; or chronic alcohol consumption. Homocysteine is an intermediate in methionine metabolism, which takes
place mainly in the liver. Impaired liver function leads to altered methionine and homocysteine metabolism; however,
the molecular basis for such alterations is not completely understood. In addition, the mechanisms behind homocysteine-
induced cellular toxicity are not fully defined. In the present work, we have examined the expression of the main
enzymes involved in methionine and homocysteine metabolism, along with the plasma levels of methionine and
homocysteine, in the liver of 26 cirrhotic patients and 10 control subjects. To gain more insight into the cellular effects
of elevated homocysteine levels, we have searched for changes in gene expression induced by this amino acid in cultured
human vascular smooth muscle cells. We have observed a marked reduction in the expression of the main genes
involved in homocysteine metabolism in liver cirrhosis. In addition, we have identified the tissue inhibitor of
metalloproteinases-1 and 1(I)procollagen to be upregulated in vascular smooth muscle cells and liver stellate cells
exposed to pathological concentrations of homocysteine. Taken together, our observations suggest (1) impaired liver
function could be a novel determinant in the development of hyperhomocysteinemia and (2) a role for elevated
homocysteine levels in the development of liver fibrosis. (Hypertension. 2001;38:1217-1221.)
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Homocysteine (Hcy) is a sulfur containing amino acid thatis formed as an intermediary in methionine metabolism
(Figure 1).1 Extensive evidence shows that elevated plasma
Hcy concentration, a reflection of impaired cellular metabo-
lism, can be considered as an independent risk factor for
atherothrombotic vascular disease (reviewed in Refsum et
al2). This condition has been observed in 20% to 30% of
patients with premature arteriosclerosis and in 21% of the
general population above a certain age.3,4 Three enzymes
utilize Hcy as a substrate: methionine synthase (MS) and
betaine-homocysteine methyltransferase (BHMT), which
convert homocysteine back to methionine, and cystathionine
-synthase (CBS), the first enzyme in the transsulfuration
pathway.1 The distribution of Hcy among them depends on
metabolic conditions: when methionine is relatively deficient
remethylation of Hcy is favored, whereas in situations of
methionine excess, the transsulfuration pathway prevails
(Figure 1).1,2 S-Adenosylmethionine (AdoMet), the first me-
tabolite of methionine, modulates the flow of Hcy through
these metabolic pathways: increased levels of AdoMet acti-
vate CBS and inhibit the activity of MS and BHMT.1,5
Impairment of Hcy remethylation or transsulfuration leads to
hyperhomocystinemia. Such situations may develop as a
consequence of genetic defects in the enzymes MS, CBS, or
methylenetetrahydrofolate reductase (the enzyme that synthe-
sizes the MS cosubstrate 5-methyltetrahydrofolate).2,3 Nutri-
tional deficiencies in vitamin B6, the cofactor of CBS, or
folates and vitamin B12, cosubstrate and cofactor of MS, can
also lead, along with impaired renal function, to
hyperhomocystinemia.2–4
The liver plays a central role in the synthesis and metab-
olism of homocysteine, given the fact that the majority of
dietary methionine is metabolized in this organ, where85%
of the whole body capacity for transmethylation resides.1,5
Accordingly, the liver displays a specific pattern of expres-
sion of genes involved in methionine and homocysteine
metabolism. There are 2 genes coding for methionine adeno-
syltransferase (MAT), the enzyme that converts methionine
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into AdoMet, one (MAT1A) is expressed exclusively in the
liver and a second gene (MAT2A) is expressed in all tissues.5
BHMT and CBS expression is confined mainly to the liver,
whereas MS is widely expressed (Figure 1).1 Thus, it is
conceivable that in situations of liver damage, alterations in
Hcy may occur. In fact, hyperhomocysteinemia has been
reported in chronic alcoholics and in patients with alcoholic
cirrhosis, as well as in experimental models of liver dam-
age.6–10 Although there is extensive evidence about the
above-mentioned genetic and nutritional determinants for
hyperhomocystinemia, knowledge of the molecular basis of
the alteration of Hcy metabolism in liver injury is still limited.
The pathological mechanisms by which elevated Hcy
promotes atherothrombotic vascular diseases are not com-
pletely known.2,3 Endothelial injury, which can lead to altered
NO production and impaired platelet modulating activity, has
been demonstrated.11–13 In addition, Hcy promotes DNA
synthesis and collagen production in vascular smooth muscle
cells (VSMCs),14,15 cholesterol production by hepatic cells,16
and lymphocyte DNA hypomethylation.17 These observations
suggest a multifactorial mechanism of action for Hcy that
may take place not only at the vascular level but on a variety
of cellular backgrounds.
In the present report, we describe our attempt to gain
further insight into the mechanisms behind the hyperhomo-
cysteinemia associated with liver damage and into the mo-
lecular basis of Hcy interference with normal cell function.
Methods
DL-Hcy was from Sigma Chemical Co.. Cell culture media, fetal
bovine serum, and antibiotics were from GIBCO-BRL. Anti-tissue
inhibitor of metalloproteinases-1 (TIMP-1) monoclonal antibody
was from Calbiochem. Anti-proliferating cell nuclear antigen
(PCNA) monoclonal antibody was from Santa Cruz Biotechnology.
Radioactive isotopes were purchased from Amersham. Restriction
enzymes were from Boehringer Mannheim, M-MLV reverse tran-
scriptase was from GIBCO-BRL, and Bio Taq DNA polymerase was
from Bioline.
Patients
We have studied a group of 26 patients (17 males and 9 females;
mean age, 548.5 years) with liver cirrhosis of different etiology (13
hepatitus C virus cirrhosis, 10 alcoholic cirrhosis, 1 hepatitis B virus
cirrhosis, 1 cryptogenetic cirrhosis, and 1 primary biliary cirrhosis).
The control group consisted of 10 subjects in whom a cholecystec-
tomy was performed for the treatment of symptomatic cholelithiasis
and who consented to have a liver biopsy during the surgical
procedure. Liver samples were immediately frozen and kept at
80°C until processed. In the subjects from the control group, both
the liver function tests and the liver biopsy were normal. The study
was approved by the human research committee of the University of
Navarra.
Animals
In vivo effects of Hcy were studied in male C57BL/6 mice (Harlan,
Barcelona, Spain) of 30 g of weight. Animals received a daily
intraperitoneal injection of Hcy (0.1 mg/g of weight)18 or saline for
4 days, and then were euthanized by cervical dislocation. Aorta was
removed, immediately frozen, and stored at 80°C. Four animals
were used per group. Studies were approved by the University of
Navarra animal research review committee.
Cell Culture
The hepatic stellate cell (HSC) clone CFSC-2G, derived from
CCl4-treated rats, was kindly provided by Dr Marcos Rojkind (Albert
Einstein College of Medicine, New York). Human and porcine
(Yucatan minipigs) VSMCs were isolated from mammary artery and
aorta, respectively, and cultured as reported.19 Cells were made
quiescent before Hcy treatment. Rat hepatocytes (from male Wistar
rats) were isolated by collagenase perfusion and cultured as report-
ed.19 The HepG2 human hepatoma cell line was from the American
type culture collection and was propagated as described.19 All
treatments were performed in serum-free medium.
Differential Display Analysis by Means of
Polymerase Chain Reaction
Differential display analysis by means of polymerase chain reaction
(DDPCR) was performed using the Hyeroglyph mRNA Profile Kit
(Genomyx, Beckman Instruments) as described.19 RNA isolation, by
the guanidinium thiocyanate method, and Northern blot analysis
were performed as reported previously.19 The probes used (1(I)pro-
collagen and -actin) have been described elsewhere.19 Quantitation
of gene expression in human liver samples was performed by reverse
transcriptase-PCR; the primers employed have been reported previ-
ously.20 The Alternate 18S Internal Standards primer set (Ambion)
was used to amplify the 18S rRNA that served as internal control.
Immunoblot Analysis
Tissue and cell samples were homogenized as described in the
presence of protease inhibitors at 4°C.19 Conditioned media from
HepG2 cells was concentrated 10-fold as reported.19 Samples were
subjected to 12% sodium dodecylsulfate-polyacrylamide gel electro-
phoresis. Proteins were electroblotted onto nitrocellulose membranes
and probed with the corresponding antibodies. Blots were developed
by enhanced chemiluminescence according to manufacturer’s in-
structions (Dupont).
Serum Methionine and Total Hcy Determination
Serum methionine and total serum Hcy (tHcyprotein-bound and
free Hcy) determinations were as described.20
Statistics
Data are meanSEM. In the human studies, the Mann-Whitney
unpaired test was used to compare groups. Otherwise, statistical
significance was estimated with Student’s t test.
Figure 1. Liver methionine cycle and transsulfuration pathway.
GNMT indicates glycine N-methyltransferase; MTs, methyltrans-
ferases; SAHH, and S-adenosylhomocysteine hydrolase, Repro-
duced from Avila M et al20 with permission from Elsevier
Science.
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Results
We have first measured the expression of liver genes in-
volved in methionine metabolism. According to the level of
expression, compared with that of control livers, cirrhotics
were divided into 3 groups: group 1, patients with very low or
non-detectable expression; group 2, patients with a level of
expression lower than that of controls (50% of the expression
found in controls); and group 3, patients with a level of
expression similar to that of controls. Human serum albumin
(HSA) expression was also measured. The distribution of
patients among these groups, and according to the etiology of
the disease (hepatitis C virus or alcoholism), is shown in
Figure 2. Individual patients with a marked reduction in the
expression of a given gene (group 1) tended to be in this same
group for all genes tested. To evaluate if the reduced
expression of the various genes involved in methionine
metabolism was related to the severity of the disease, ex-
pressed as the Child-Pugh score,21 patients were divided into
2 groups. One group (group A) included patients showing
normal or only reduced levels of mRNA for at least 3 of the
5 genes analyzed that were involved in methionine metabo-
lism. The second group (group B) included those patients
with very low or undetectable levels of mRNA for all or 4 of
the 5 genes analyzed involved in methionine metabolism. The
mean value for the Child-Pugh score was significantly higher
in the cirrhotic patients in group B (9.00.7) than in the
cirrhotic patients in group A (7.10.4, P0.03).
The mean value for serum Hcy was significantly higher in
the cirrhotic patients in group B than in group A (Figure 3).
Accordingly, mean Hcy concentration was significantly
higher for all cirrhotics (14.11.3 mol/L) than for the
control group (8.10.9 mol/L, P0.03). In agreement with
previous publications,5,22 fasting serum methionine was
higher in cirrhotics (106.334.7 mol/L) than in the control
group (30.84.8 mol/L, P0.01). Differences in methio-
nine concentration in cirrhotic patients in groups A and B
were also statistically significant (Figure 3).
The second aim of this work was to improve our knowl-
edge on the molecular basis of cellular Hcy effects. We
observed that Hcy treatment of quiescent human VSMCs
induces the expression of PCNA, a marker of cellular
proliferation (Figure 4A). This effect was also observed when
Hcy was administered to mice, and PCNA expression was
determined in aortic tissue (Figure 4B). We have searched for
other genes with expression that could be altered by Hcy in
cultured human VSMCs by DDPCR. Cells were made qui-
escent by serum deprivation and then treated with 100
mol/L of Hcy, a concentration compatible with intermediate
hyperhomocystinemia,2 for 24 hours. By DDPCR analysis,
we have identified TIMP-1 to be upregulated in response to
Hcy treatment (2-fold induction) (Figure 5A and 5B). This
effect was also observed in pig aorta–cultured VSMCs
(Figure 5C). Moreover, intraperitoneal administration of Hcy
to mice also resulted in the induction of TIMP-1 expression in
Figure 2. Expression of liver methionine metab-
olizing genes and serum albumin (HSA) in cir-
rhotic patients according to the etiology of the
disease. Patient groups are defined in the text,
and gene names are defined in the text or in
the legend for Figure 1. The percentage of
patients in each group is shown. Reproduced
from Avila M et al20 with permission from
Elsevier Science.
Figure 3. Serum levels of methionine
and Hcy in control and cirrhotic patients
(all 26 patients). Groups A and B are
defined in the text.
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aorta (Figure 5D). TIMP-1 plays an important role in the
regulation of extracellular matrix (ECM) homoeostasis,23
which is essential not only in the vessel wall but also in the
liver.24 Consequently, we have studied TIMP-1 and 1(I)pro-
collagen expression in rat HSCs, observing that both genes
are time and dose dependently induced by Hcy in this cell
type (Figure 6A and 6B). This effect of Hcy on TIMP-1
expression was also extended to rat hepatocytes and HepG2
cells (Figure 6C and 6D).
Discussion
Our results show that alterations in Hcy metabolism in human
liver cirrhosis can be ascribed in part to a marked reduction in
the expression of the main genes involved in its metabolism,
namely MS, BHMT, and CBS. The expression of these genes
was always more compromised than that of HSA and was
related to the severity of the disease, expressed as the
Child-Pugh score. We observe reduced expression of Hcy-
metabolizing genes, both in alcoholism and hepatitis C virus
cirrhosis. It has been suggested that impairment of Hcy
metabolism in cirrhosis can be also related to decreased
availability or utilization of vitamins B6, B12, or folates,8
which is possible. However, our present data on hyperhomo-
cysteinemia in cirrhosis has been confirmed in other human
and experimental studies in which hyperhomocysteinemia
was not associated with altered plasma levels of the above-
mentioned vitamins.25,26 We also observed a decrease in
MAT1A expression in cirrhotic liver, which contributes to the
reported hypermethioninemia and impairment of AdoMet
synthesis in this condition.5 We have previously shown that
AdoMet treatment of cirrhotic rats reduces elevated plasma
Hcy.10 Reduced AdoMet levels plus impaired CBS expres-
sion in cirrhotics may result in decreased flow of Hcy through
Figure 4. Western blot analysis of PCNA expression in quies-
cent human VSMCs treated with Hcy (100 to 300 mol/L) or
FBS for 48 hours (A) and aortic tissue from control (saline) and
Hcy-treated mice (as described in Methods) (B). Representative
blots are shown (n4).
Figure 5. A, Detection of differential gene expression induced
by Hcy in quiescent human VSMCs (24-hour treatment with 100
mol/L Hcy) by DDPCR. B, Representative Northern blot analy-
sis performed with cloned band from DDPCR gel, identified as
TIMP-1, on control and Hcy-treated human VSMCs (24 hours,
100 mol/L Hcy). C, Northern blot analysis of TIMP-1 in pig
VSMCs treated as in panel B. D, Western blot analysis of
TIMP-1 expression in aortic tissue from control (saline) and Hcy-
treated mice (as described in Methods). Representative blots
are shown (n4). Taken in part from Torres et al19 with permis-
sion from Elsevier Science.
Figure 6. A, Northern blot analysis of TIMP-1 expression in rat
HSCs treated for 4 hours with Hcy. B, Northern blot analysis of
1(I)procollagen expression in rat HSCs treated for 4 hours with
Hcy. C, Northern blot analysis of TIMP-1 expression in rat hepa-
tocytes treated with 500 mol/L Hcy. D, Western blot analysis
of TIMP-1 in conditioned medium from Hcy-treated (24-hour
treatment) HepG2 cells. Reproduced from Torres et al19 with
permission from Elsevier Science.
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the transsulfuration pathway and contributes to the hyperho-
mocysteinemia associated with this condition.
We have also addressed the cellular consequences of
elevated Hcy levels. Our observations of increased PCNA
expression in cultured human VSMCs and in aortic mouse
tissue contribute to explain the growth promoting effects
described for Hcy in the arterial tissue.3,11,14 Our DDPCR
study identified TIMP-1 as a gene upregulated by Hcy in
human and pig cultured VSMCs. This observation was also
made in vivo, when administration of Hcy to mice increased
TIMP-1 protein in aortic tissue. TIMP-1 is an essential
component of the ECM regulating system, acting as an
inhibitor of matrix metalloproteinases involved in collagen
degradation.23 Hcy-promoted cell growth and TIMP-1 ex-
pression, together with the reported induction of collagen
synthesis in VSMCs treated with Hcy,13,15 may lead to altered
ECM remodeling, intimal fibrosis, and cardiovascular dys-
function. The control of ECM homeostasis is important in
most tissues, but it is central to preserve liver function. Liver
fibrosis occurs at the onset of most situations of chronic liver
damage.24 Hcy-induced 1(I)procollagen expression in HSCs
and TIMP-1 induction in HSCs and hepatocytes suggest that
the previously mentioned profibrogenic effects of Hcy in the
vascular bed could be extended to the liver tissue. Interest-
ingly, in CCl4-treated rats hyperhomocysteinemia develops
before liver fibrosis,10 and AdoMet treatment downregulates
plasma Hcy levels and diminishes collagen deposition.5 Hcy
may thus cooperate in the onset of liver fibrosis potentiating
the effect of other agents, such as ethanol and cytokines. In
support of this hypothesis is the observation that the admin-
istration of a vitamin B12/cobalt-defficient diet to lambs
results in hyperhomocystinemia, which is accompanied by
the development of liver steatosis and periportal fibrosis.27
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